Graham A-MPE-lifies its Medical Devices & Life Sciences Portfolio

Acquires Medical Device Manufacturer, Midwest Products & Engineering

Graham Partners (“Graham”), a private investment firm targeting advanced manufacturing and technology-enabled services businesses, is pleased to announce the acquisition of Midwest Products & Engineering (“MPE” or the “Company”), a medical device manufacturer specializing in complex electromechanical and robotic-assisted surgical systems.

Headquartered in Milwaukee, Wisconsin, MPE is a contract development and manufacturing organization (“CDMO”) that primarily partners with medical device companies to design, engineer, and integrate electromechanical systems used in robotic‑assisted surgery, surgical navigation, cardiology, imaging, and electrosurgical applications. Graham believes the Company is benefiting from an industry-wide conversion toward outsourcing as medical device companies focus on accelerating speed to market, reducing internal manufacturing complexity, and prioritizing R&D, sales, and marketing competencies. Further, MPE is positioned to benefit from growth in minimally invasive surgeries and an aging global population, which is driving incremental demand for medical device manufacturing partners like MPE that aid in delivering high-quality, cost-efficient solutions.

Over the 40+ years since its founding, MPE has evolved into a vertically integrated CDMO, partnering with customers from the initial design through full-scale manufacturing, assembly, and distribution. Today, MPE‑supported systems help surgeons deliver more precise, less invasive care, from real‑time, 3D surgical navigation platforms to non‑invasive technologies used to treat tumors without surgery.

Graham Partners will seek to accelerate growth at MPE by investing in and helping advance engineering, sales, and operational initiatives at the Company, continuing to support MPE’s existing operating model and customer relationships. With existing medical contract manufacturing investments in current portfolio companies, Smithstown and Velosity, and its prior investment in Medbio, Graham intends to leverage its MedTech expertise and deep industry advisor network to support MPE’s continued growth. Joe Heinmiller, Managing Partner at Graham Partners, said, “MPE represents a unique platform in the MedTech CDMO landscape. We believe the Company’s focus on advanced electromechanical systems, longstanding customer relationships, and engineering‑driven culture position it for continued success in an increasingly complex and fast‑growing niche within the broader MedTech market.” Megan Barsella Van Leer, Vice President at Graham Partners, added, “We look forward to partnering with the MPE team to support the business as it scales, to strengthen its OEM partnerships, and to continue expanding its role in working alongside OEMs to drive advances in next-generation medical technologies.”

About MPE

MPE is a medical device contract development and manufacturing organization specializing in complex electromechanical medical systems used across robotic-assisted surgery, surgical navigation, cardiology, imaging, and electrosurgery therapeutic areas, among others. Headquartered in Milwaukee, Wisconsin, the Company offers end‑to‑end solutions spanning design and engineering, metal fabrication, assembly, testing, and distribution to its blue-chip and emerging OEM customers.

FOR FURTHER INFORMATION CONTACT:  

Joe Heinmiller (jheimiller@grahampartners.net)
Megan Barsella Van Leer (mbarsella@grahampartners.net)
Tel: (610) 408-0500
www.grahampartners.net
Graham Partners on Video

Legal Disclaimer This press release is for informational purposes and is not an offer to sell, or a solicitation of an offer to buy, securities in the United States or elsewhere. Graham Partners is not utilizing this release to provide investment or other advice, and no information disclosed therein is to be relied upon for the purpose of making investment decisions. Past performance does not guarantee future results and any transactions described are included as representative transactions and are not necessarily reflective of overall performance. It should not be assumed that any investment described herein was or will be profitable. There can be no assurance that historical trends will continue. Graham Partners’ market characterization is based on subjective determinations that it believes reasonable but others may disagree with such characterization. There is no guarantee that Graham Partners’ initiatives will drive value for its investments or accelerate growth or lead Graham Partners’ investments to become profitable.